Inhibitor Therapeutics, Inc. — Income Charts
38 quarters of history · ending 2022-09-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$0
Operating Income↓-5.6% -$4K
$-70K
EBITDA↓-5.6% -$4K
$-70K
Interest Expense
$8K
Net Income↓-9.3% -$7K
$-78K
Operating Margin↑+3229.3pts
-29424.9%
Net Margin↑+3229.3pts
-29324.9%
ETR Federal Statutory
—
ETR State + Local (pp)
—
Operating Lease Cost
—
Revenue YoY Variation
-100.0%
Income YoY Variation↓-83.8pts
-5.6%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+6.9pts
1.2%